Brokerages Expect Heron Therapeutics, Inc. (NASDAQ:HRTX) Will Announce Quarterly Sales of $22.00 Million

Equities analysts predict that Heron Therapeutics, Inc. (NASDAQ:HRTXGet Rating) will announce $22.00 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Heron Therapeutics’ earnings. The highest sales estimate is $23.00 million and the lowest is $21.00 million. Heron Therapeutics reported sales of $20.02 million during the same quarter last year, which would indicate a positive year over year growth rate of 9.9%. The company is expected to issue its next earnings results after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Heron Therapeutics will report full-year sales of $112.40 million for the current financial year, with estimates ranging from $105.00 million to $119.80 million. For the next financial year, analysts expect that the firm will report sales of $174.75 million, with estimates ranging from $174.50 million to $175.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTXGet Rating) last released its quarterly earnings results on Monday, February 28th. The biotechnology company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. The company had revenue of $20.66 million during the quarter, compared to analysts’ expectations of $25.77 million. Heron Therapeutics had a negative return on equity of 159.70% and a negative net margin of 255.58%. Heron Therapeutics’s quarterly revenue was up .2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.68) EPS.

A number of equities analysts have commented on HRTX shares. Needham & Company LLC reduced their target price on Heron Therapeutics from $24.00 to $16.00 in a report on Tuesday, March 1st. StockNews.com started coverage on Heron Therapeutics in a report on Thursday, March 31st. They set a “sell” rating for the company. Cowen dropped their price target on Heron Therapeutics from $31.00 to $13.00 in a research report on Tuesday, March 1st. Cantor Fitzgerald dropped their price target on Heron Therapeutics from $26.00 to $20.00 and set an “overweight” rating for the company in a research report on Tuesday, March 1st. Finally, Zacks Investment Research lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, February 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $18.46.

A number of institutional investors have recently modified their holdings of the stock. State Street Corp grew its position in Heron Therapeutics by 18.5% in the fourth quarter. State Street Corp now owns 7,692,411 shares of the biotechnology company’s stock worth $70,232,000 after acquiring an additional 1,200,504 shares during the period. BlackRock Inc. grew its position in Heron Therapeutics by 2.0% in the third quarter. BlackRock Inc. now owns 7,672,868 shares of the biotechnology company’s stock worth $82,023,000 after acquiring an additional 151,019 shares during the period. ArrowMark Colorado Holdings LLC grew its position in Heron Therapeutics by 8.8% in the third quarter. ArrowMark Colorado Holdings LLC now owns 6,421,335 shares of the biotechnology company’s stock worth $68,644,000 after acquiring an additional 517,367 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Heron Therapeutics by 18.0% during the fourth quarter. JPMorgan Chase & Co. now owns 6,254,766 shares of the biotechnology company’s stock worth $57,105,000 after buying an additional 952,969 shares during the period. Finally, Palisade Capital Management LLC NJ boosted its position in shares of Heron Therapeutics by 21.8% during the fourth quarter. Palisade Capital Management LLC NJ now owns 3,034,172 shares of the biotechnology company’s stock worth $27,702,000 after buying an additional 542,589 shares during the period.

NASDAQ HRTX opened at $4.11 on Friday. The stock has a market capitalization of $419.80 million, a price-to-earnings ratio of -1.83 and a beta of 1.37. Heron Therapeutics has a twelve month low of $3.95 and a twelve month high of $18.80. The company has a current ratio of 3.58, a quick ratio of 2.90 and a debt-to-equity ratio of 1.92. The stock has a 50-day moving average of $5.39 and a 200 day moving average of $7.99.

About Heron Therapeutics (Get Rating)

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Stories

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.